387 related articles for article (PubMed ID: 11253504)
21. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.
Bansi DS; Chapman RW; Fleming KA
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):881-5. PubMed ID: 8889455
[TBL] [Abstract][Full Text] [Related]
22. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.
Herrlinger KR; Noftz MK; Dalhoff K; Ludwig D; Stange EF; Fellermann K
Am J Gastroenterol; 2002 Feb; 97(2):377-81. PubMed ID: 11866276
[TBL] [Abstract][Full Text] [Related]
23. Focal gastric inflammatory infiltrates in inflammatory bowel diseases: prevalence, immunohistochemical characteristics, and diagnostic role.
Parente F; Cucino C; Bollani S; Imbesi V; Maconi G; Bonetto S; Vago L; Bianchi Porro G
Am J Gastroenterol; 2000 Mar; 95(3):705-11. PubMed ID: 10710061
[TBL] [Abstract][Full Text] [Related]
24. Inflammatory bowel disease in Iran: a review of 457 cases.
Aghazadeh R; Zali MR; Bahari A; Amin K; Ghahghaie F; Firouzi F
J Gastroenterol Hepatol; 2005 Nov; 20(11):1691-5. PubMed ID: 16246187
[TBL] [Abstract][Full Text] [Related]
25. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.
Vavricka SR; Brun L; Ballabeni P; Pittet V; Prinz Vavricka BM; Zeitz J; Rogler G; Schoepfer AM
Am J Gastroenterol; 2011 Jan; 106(1):110-9. PubMed ID: 20808297
[TBL] [Abstract][Full Text] [Related]
26. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors.
Simrén M; Axelsson J; Gillberg R; Abrahamsson H; Svedlund J; Björnsson ES
Am J Gastroenterol; 2002 Feb; 97(2):389-96. PubMed ID: 11866278
[TBL] [Abstract][Full Text] [Related]
27. [Enteropathic spondylarthritis in chronic inflammatory bowel diseases: prevalence, manifestation pattern and HLA association].
Protzer U; Duchmann R; Höhler T; Hitzler W; Ewe K; Wanitschke R; Meyer zum Büschenfelde KH; Märker-Hermann E
Med Klin (Munich); 1996 Jun; 91(6):330-5. PubMed ID: 8767304
[TBL] [Abstract][Full Text] [Related]
28. [Erythema nodosum and Crohn's disease].
Areias E; García E Silva L
Med Cutan Ibero Lat Am; 1984; 12(6):489-95. PubMed ID: 6152299
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
30. [Clinical analysis of cutaneous manifestations and related factors in patients with ulcerative colitis].
Tian Y; Li JX; Wang HH; Li RY; Liu XG
Zhonghua Nei Ke Za Zhi; 2016 Jul; 55(7):505-9. PubMed ID: 27373283
[TBL] [Abstract][Full Text] [Related]
31. Review article: skin complications associated with inflammatory bowel disease.
Tavarela Veloso F
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():50-3. PubMed ID: 15352894
[TBL] [Abstract][Full Text] [Related]
32. Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy.
Passarini B; Infusino SD; Barbieri E; Varotti E; Gionchetti P; Rizzello F; Morselli C; Tambasco R; Campieri M
Dermatology; 2007; 215(4):295-300. PubMed ID: 17911986
[TBL] [Abstract][Full Text] [Related]
33. Important cutaneous manifestations of inflammatory bowel disease.
Trost LB; McDonnell JK
Postgrad Med J; 2005 Sep; 81(959):580-5. PubMed ID: 16143688
[TBL] [Abstract][Full Text] [Related]
34. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease.
Romberg-Camps MJ; Dagnelie PC; Kester AD; Hesselink-van de Kruijs MA; Cilissen M; Engels LG; Van Deursen C; Hameeteman WH; Wolters FL; Russel MG; Stockbrügger RW
Am J Gastroenterol; 2009 Feb; 104(2):371-83. PubMed ID: 19174787
[TBL] [Abstract][Full Text] [Related]
35. Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
Roth N; Biedermann L; Fournier N; Butter M; Vavricka SR; Navarini AA; Rogler G; Scharl M;
PLoS One; 2019; 14(1):e0210436. PubMed ID: 30682031
[TBL] [Abstract][Full Text] [Related]
36. [Cutaneous manifestations with ulcerative colitis].
Arai S; Katsuoka K
Nihon Rinsho; 1999 Nov; 57(11):2571-4. PubMed ID: 10572433
[TBL] [Abstract][Full Text] [Related]
37. Inflammatory bowel disease in Scottish children.
Bland RM; Evans TJ; Raine P; Weaver LT
Health Bull (Edinb); 1999 Nov; 57(6):365-73. PubMed ID: 12811868
[TBL] [Abstract][Full Text] [Related]
38. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase.
Rocha R; Santana GO; Almeida N; Lyra AC
Br J Nutr; 2009 Mar; 101(5):676-9. PubMed ID: 18631418
[TBL] [Abstract][Full Text] [Related]
39. Previous experience and quiality of life in patients with inflammatory bowel disease during relapse.
Casellas F; López Vivancos J; Malagela JR
Rev Esp Enferm Dig; 2003 Jul; 95(7):476-9, 471-5. PubMed ID: 12952508
[TBL] [Abstract][Full Text] [Related]
40. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease.
Summers RW; Elliott DE; Qadir K; Urban JF; Thompson R; Weinstock JV
Am J Gastroenterol; 2003 Sep; 98(9):2034-41. PubMed ID: 14499784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
